Table 5.
Linear mixed model and post hoc analysis results for therapeutic subgroup comparison (cyclin-dependent kinase 4/6 inhibitors +/– endocrine therapy = group 1, chemotherapy = group 2, endocrine therapy = group 3, human epidermal growth factor receptor 2-targeted therapy = group 4); scale of the respective tool in brackets.
| Group comparison | EQ-VASa (0-100) | EQ-5D-5Lb (0-1) | EORTC QLQ-C30c (0-100) | ||||
|
|
Estimate | P value | Estimate | P value | Estimate | P value | |
| Overall | —d | <.001 | — | .002 | — | .048 | |
| 2-1 | –14.41 | <.001 | –0.06 | .03 | 8.91 | .04 | |
| 3-1 | –12.62 | <.001 | –0.26 | .79 | 1.74 | .97 | |
| 4-1 | –10.58 | <.001 | 0.01 | .99 | 3.37 | .75 | |
| 3-2 | 1.80 | .81 | 0.04 | .47 | –7.17 | .23 | |
| 4-2 | 3.83 | .09 | 0.07 | .002 | –5.54 | .29 | |
| 4-3 | 2.03 | .75 | 0.03 | .58 | 1.63 | .97 | |
aEQ-VAS: EuroQol Visual Analog Scale.
bEQ-5D-5L: EuroQol 5 Dimension 5 Level.
cEORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire–Core 30 item.
dNot applicable.